Headline News

 

Johnson’s TECVAYLI monotherapy submitted for relapsed/refractory multiple myeloma after at least one prior therapy

Posted on March 16, 2026

Johnson & Johnson announces approval of TECNIS PureSee Intraocular Lens

Posted on March 16, 2026

Johnson & Johnson highlights first-in-human Erda-iDRS results in intermediate risk non muscle invasive bladder cancer

Posted on March 16, 2026

GSK and Alfasigma’s agreement on worldwide rights for linerixibat

Posted on March 16, 2026

GSK announces top antimicrobial resistance benchmark report

Posted on March 16, 2026

Arexvy approved in US for expanded age indication in adults aged 18–49 years at increased risk

Posted on March 16, 2026

Enhertu receives priority review as post-neoadjuvant treatment for patients with HER2-positive early breast cancer

Posted on March 16, 2026

Imfinzi approved as the first and only perioperative immunotherapy for patients with early gastric and gastroesophageal cancers

Posted on March 16, 2026

Pfizer’s update on their phase 2 study of trispecific antibody positive in moderate to severe atopic dermatitis

Posted on March 16, 2026

Roche releases new update on phase 3 persevERA study in ER-positive advanced breast cancer

Posted on March 10, 2026

Vertex set to present data on JOURNAVX that highlights effective pain management following aesthetic and reconstructive procedures

Posted on March 10, 2026

Vertex releases positive interim analysis results for primary and all secondary endpoints in phase 3 trial of Povetacicept

Posted on March 10, 2026

Enhertu receives priority review for post-neoadjuvant treatment for patients with HER2-positive early breast cancer

Posted on March 10, 2026

Pfizer’s update on phase 2 study of trispecific antibody positive in moderate to severe atopic dermatitis

Posted on March 10, 2026

GSK’s acquisition of RAPT Therapeutics

Posted on March 10, 2026